Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC
Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Source: onclive.com
Translational Integration News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Translational Integration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Translational Integration Today - Breaking & Trending Today
Dr Kopetz on Adagrasib Plus Cetuximab in KRAS G12C+ mCRC
Scott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.
Source: onclive.com
AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated m
Source: newswise.com
Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC
Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.
Source: onclive.com
AACR: MD Anderson's Scott Kopetz and Elizabeth Travis honored with 2024 Scientific Achievement Awards
Two researchers from The University of Texas MD Anderson Cancer Center will be honored with Scientific Achievement Awards at the American Association for Cancer
Source: newswise.com